ArticleCureus2025

Correction: Reduction of Cardiovascular Risk Using Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Acute Coronary Syndrome: A Systematic Review.

Ahmad M Rabih et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.